Articles related to HEART FAILURE (HF)

SGLT-2 inhibitors have emerged as a cornerstone in managing HFrEF and CKD, demonstrating substantial reductions in cardiovascular and renal adverse outcomes. This class of medications is reshaping the therapeutic approach in patients with these comorbid conditions, providing a dual benefit that was once considered challenging to achieve.

Experience an in-depth exploration of heart failure management in Mont-Tremblant, Canada, where you’ll delve into the latest diagnostic and therapeutic advancements, gaining insights that are crucial for enhancing patient outcomes in your practice.

Marlex Pharmaceuticals has initiated a critical recall of specific lots of Digoxin Tablets due to a labeling error. Physicians are urged to exercise extreme caution and verify their inventory to prevent adverse patient outcomes.

Explore the potential of technology in enhancing medication adherence among heart failure patients and the need for more robust research in this area.

Despite the demonstrated benefits of the recommended quadruple therapy for heart failure, its cost-effectiveness is highly sensitive to drug pricing, necessitating more thorough scrutiny and potential policy interventions to ensure equitable patient access.

Dive into how the FDA-approved Farxiga is changing the heart failure treatment landscape. Colleagues, let’s dive into a remarkable milestone. Farxiga, known as dapagliflozin, now has FDA approval. This is groundbreaking for heart failure treatment. It applies to all patients, regardless of their left ventricular ejection fraction (LVEF) status. The approval didn’t happen overnight. Let’s talk about the DELIVER trial, a vital part of the process. It involved over 6,000 patients, all over 40. Each had heart failure, LVEF above 40%, and may or may not have had type 2 diabetes. They took either dapagliflozin or a placebo daily, plus their usual therapy. The trial had a clear goal: time to the first composite event. This included CV death, heart failure hospitalization, or an urgent heart failure visit. The goal applied to everyone, including patients with LVEF less than 60%. Fast forward about 2.3 years, the results were significant. Dapagliflozin cut the composite outcome by 18% versus the placebo. Both worsening heart failure and CV death rates dropped in the dapagliflozin group. The best part? These findings were consistent, even in patients with lower LVEF or diabetes. Expanding the picture, let’s consider two trials together: DELIVER and DAPA-HF. Over 22 […]